Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Nikolaou A, Ambavane A, Shah A, Ma W, Tosh J, Kapetanakis V, Willson J, Wang F, Hogea C, Gorsh B, Gutierrez B, Sapra S, Suvannasankha A, Samyshkin Y. Nikolaou A, et al. Among authors: samyshkin y. Expert Rev Hematol. 2021 Dec;14(12):1137-1145. doi: 10.1080/17474086.2021.1970522. Epub 2021 Sep 20. Expert Rev Hematol. 2021. PMID: 34465265
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.
Hoogendoorn M, Feenstra TL, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs AH, Lloyd A, Sullivan SD, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: samyshkin y. Value Health. 2014 Jul;17(5):525-36. doi: 10.1016/j.jval.2014.03.1721. Epub 2014 May 14. Value Health. 2014. PMID: 25128045 Free article.
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson SA, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Mölken MPMH. Hoogendoorn M, et al. Among authors: samyshkin y. Value Health. 2016 Sep-Oct;19(6):800-810. doi: 10.1016/j.jval.2016.04.002. Epub 2016 May 21. Value Health. 2016. PMID: 27712708 Free article.
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.
Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R, Risebrough N, Samyshkin Y, Wacker M, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: samyshkin y. Value Health. 2017 Mar;20(3):397-403. doi: 10.1016/j.jval.2016.10.016. Epub 2017 Jan 3. Value Health. 2017. PMID: 28292484 Free article.
Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (COPD): Cross-Model Comparison of Hypothetical Treatment Scenarios.
Hoogendoorn M, Feenstra T, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs A, Lloyd A, Sullivan SD, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: samyshkin y. Value Health. 2014 Nov;17(7):A557-8. doi: 10.1016/j.jval.2014.08.1836. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201829 Free article. No abstract available.
31 results